An observational study in Schizophrenia, sponsored by AstraZeneca. Completed at 15 sites in Latvia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-10.
Sponsored by AstraZeneca · Observational
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's planned enrollment of 80 is below the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
primary care clinics
Exclusion Criteria:
Adult schizophrenia patients already on Seroquel XR therapy
Improvement in CGI scores and BPRS comparing visits 1 and 3.
Time frame: twice with 4 week interval
To evaluate compliance to therapy
Time frame: twice with 4 week interval
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca